Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pseudomonas Aeruginosa Infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43876   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Pseudomonas Aeruginosa Infection. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-002318-22 Sponsor Protocol Number: CTBM100C2303 Start Date*: 2009-09-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a ...
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016734-26 Sponsor Protocol Number: CTBM100C2303E2 Start Date*: 2010-01-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who succ...
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004764-39 Sponsor Protocol Number: CTBM100C2303E1 Start Date*: 2009-09-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Comp...
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002000-32 Sponsor Protocol Number: CTBM100C2401 Start Date*: 2011-11-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Ongoing) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001728-30 Sponsor Protocol Number: MPEX-204 Start Date*: 2008-08-26
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP- 376 Solution for Inhalation Given for 2...
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024606-34 Sponsor Protocol Number: 2010-PI-0521 Start Date*: 2011-04-11
    Sponsor Name:Mª Victoria Gil Navarro
    Full Title: Eficacia y seguridad de Piperacilina/Tazobactam administrada en perfusión continua versus infusión intermitente en pacientes con infección complicada o nosocomial con sospecha o aislamiento de Pseu...
    Medical condition: infecciones complicadas o de origen nosocomial con sospecha o aislamiento de Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    13 10021860 Infección por Pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019634-26 Sponsor Protocol Number: MPEX-209 Start Date*: 2011-05-24
    Sponsor Name:Mpex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients
    Medical condition: Pseudomonas aeruginosa infection in patients suffering from stable Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    14.0 10021881 - Infections and infestations 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Ongoing) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005037-30 Sponsor Protocol Number: IC43-201 Start Date*: 2008-11-20
    Sponsor Name:Intercell AG
    Full Title: A PHASE 2 PILOT STUDY ASSESSING IMMUNOGENICITY AND SAFETY OF IC43 IN INTENSIVE CARE PATIENTS
    Medical condition: Nosocomial Pseudomonas aeruginosa infections in mechanically ventilated ICU patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061471 Pseudomonas infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016590-15 Sponsor Protocol Number: CTBM100C2304 Start Date*: 2009-12-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infection...
    Medical condition: Lung colonisation with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    14.1 100000004862 10068292 Pseudomonas colonization LLT
    14.1 100000004862 10068297 Pseudomonas colonisation LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003532-23 Sponsor Protocol Number: CTBM100C2401E1 Start Date*: 2012-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis
    Medical condition: Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    14.1 100000004862 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004771-36 Sponsor Protocol Number: IC43-202 Start Date*: 2012-01-19
    Sponsor Name:Valneva Austria GmbH
    Full Title: A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.
    Medical condition: Nosocomial Pseudomonas aeruginosa infections in mechanically ventilated ICU patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10061471 Pseudomonas infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001769-27 Sponsor Protocol Number: CHI0465 Start Date*: 2008-09-29
    Sponsor Name:Southampton University Hospital Trust
    Full Title: Microbiological assessment of prophylactic ciprofloxacin therapy for children with cystic fibrosis during viral respiratory viral infection to prevent Pseudomonas aeruginosa colonisation – a random...
    Medical condition: Cystic Fibrosis Specifically the trial will include children aged 2-14 years with a diagnosis of cystic fibrosis and not chronically infected with pseudomonas aeruginosa in their lungs.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002202-31 Sponsor Protocol Number: POL7080-002 Start Date*: 2013-09-11
    Sponsor Name:Polyphor Ltd.
    Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of...
    Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003847-10 Sponsor Protocol Number: SHORTENII Start Date*: 2022-01-12
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
    Full Title: Efficacy and safety of 7 versus 14 days of antibiotic treatment for Pseudomonas aeruginosa bacteraemia: a multicentre, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis
    Medical condition: Adult patients with bloodstream infections produced by Pseudomonas aeruginosa.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    22.1 10021881 - Infections and infestations 10037132 Pseudomonal infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003399-58 Sponsor Protocol Number: COPTRIN1 Start Date*: 2017-01-14
    Sponsor Name:COP:TRIN Region Hovedstaden (Gentofte hospital)
    Full Title: Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease): Can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa infected patients with chronic pulmonary obstructiv...
    Medical condition: Respiratory tract infection Bacterial infection with Pseudomonas aeruginosa Chronic obstructive pulmonary disease (COPD) Non-cystic fibrosis bronchiectasis Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003275-12 Sponsor Protocol Number: AZI/SCAND/01 Start Date*: 2007-05-23
    Sponsor Name:Copenhagen CF-centre
    Full Title: Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprof...
    Medical condition: Cystic fibrosis with intermittent colonization of the airways with pseudomonas aeruginosa.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011763 Cystic fibrosis lung LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) NO (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000396-26 Sponsor Protocol Number: EA-US-205-0111 Start Date*: 2015-02-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disea...
    Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003810-35 Sponsor Protocol Number: BMX-04-001 Start Date*: 2023-04-25
    Sponsor Name:BiomX Ltd.
    Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...
    Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    22.1 100000004862 10082869 Chronic Pseudomonas aeruginosa infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006215-68 Sponsor Protocol Number: CMA-0631-PR-0010 Start Date*: 2008-07-29
    Sponsor Name:Chiesi Farmaceutici S.p.A
    Full Title: A MULTICENTRE,MULTINATIONAL, OPEN-LABEL, RANDOMISED, PARALLEL GROUP CLINICAL TRIAL OF TOBRINEB®/ACTITOB®/ BRAMITOB® (TOBRAMYCIN SOLUTION FOR NEBULISATION, 300 MG TWICE DAILY IN 4 ML UNIT DOSE VIALS...
    Medical condition: cystic fibrosis and P. aeruginosa chronic infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057582 Lung infection pseudomonal LLT
    9.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005366-19 Sponsor Protocol Number: ARD-3150-1202 Start Date*: 2014-04-29
    Sponsor Name:Aradigm Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subje...
    Medical condition: Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10057582 Lung infection pseudomonal LLT
    16.1 100000004855 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) RO (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 13 00:03:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA